These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37079787)

  • 1. The Economic Impact of Living Cell Tissue Products in Treating Diabetic Foot Ulcers and Venous Leg Ulcers in Patients with Commercial Insurance: A Retrospective Matched-Cohort Study.
    Barbul A; Gelly H; Obradovic K; Landsman A
    Adv Skin Wound Care; 2023 May; 36(5):243-248. PubMed ID: 37079787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Health Economic Impact of Living Cell Tissue Products in the Treatment of Chronic Wounds: A Retrospective Analysis of Medicare Claims Data.
    Barbul A; Gelly H; Masturzo A
    Adv Skin Wound Care; 2020 Jan; 33(1):27-34. PubMed ID: 31573991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.
    Rice JB; Desai U; Ristovska L; Cummings AK; Birnbaum HG; Skornicki M; Margolis DJ; Parsons NB
    J Med Econ; 2015; 18(8):586-95. PubMed ID: 25786331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers.
    Langer A; Rogowski W
    BMC Health Serv Res; 2009 Jul; 9():115. PubMed ID: 19591680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Placental Allografts in the Treatment of Diabetic Lower Extremity Ulcers and Venous Leg Ulcers in U.S. Medicare Beneficiaries: A Retrospective Observational Cohort Study Using Real-World Evidence.
    Padula WV; Ramanathan S; Cohen BG; Rogan G; Armstrong DG
    Adv Wound Care (New Rochelle); 2024 Jul; 13(7):350-362. PubMed ID: 38588554
    [No Abstract]   [Full Text] [Related]  

  • 6. Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(7):1-165. PubMed ID: 34211616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
    Curran MP; Plosker GL
    BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of venous leg ulcers using bilayered living cellular construct.
    Sawad AB; Turkistani F
    J Comp Eff Res; 2020 Sep; 9(13):907-918. PubMed ID: 32969709
    [No Abstract]   [Full Text] [Related]  

  • 9. A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers.
    Stone RC; Stojadinovic O; Rosa AM; Ramirez HA; Badiavas E; Blumenberg M; Tomic-Canic M
    Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cost-Effectiveness Analysis Comparing Single-use and Traditional Negative Pressure Wound Therapy to Treat Chronic Venous and Diabetic Foot Ulcers.
    Kirsner RS; Delhougne G; Searle RJ
    Wound Manag Prev; 2020 Mar; 66(3):30-36. PubMed ID: 32294054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Observed impact of skin substitutes in lower extremity diabetic ulcers: lessons from the Medicare Database (2015-2018).
    Armstrong DG; Tettelbach WH; Chang TJ; De Jong JL; Glat PM; Hsu JH; Kelso MR; Niezgoda JA; Tucker TL; Labovitz JM
    J Wound Care; 2021 Jul; 30(Sup7):S5-S16. PubMed ID: 34256590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryopreserved Placental Membrane Allograft Reduces the Likelihood of Developing a New or Recurring Foot Ulcer and All-Cause Mortality in Diabetic Patients When Compared with Other Cellular- and Tissue-Based Products.
    DaVanzo J; Hartzman A; Surfield C; Dobson A
    Adv Wound Care (New Rochelle); 2023 Apr; 12(4):169-176. PubMed ID: 35262428
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: a systematic review and meta-analysis examining how to dress for success.
    Saco M; Howe N; Nathoo R; Cherpelis B
    Dermatol Online J; 2016 Aug; 22(8):. PubMed ID: 27617934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness of a bilayered living cellular construct and a porcine collagen wound dressing in the treatment of venous leg ulcers.
    Marston WA; Sabolinski ML; Parsons NB; Kirsner RS
    Wound Repair Regen; 2014; 22(3):334-40. PubMed ID: 24628712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Race, Ethnicity, and Rurality With Major Leg Amputation or Death Among Medicare Beneficiaries Hospitalized With Diabetic Foot Ulcers.
    Brennan MB; Powell WR; Kaiksow F; Kramer J; Liu Y; Kind AJH; Bartels CM
    JAMA Netw Open; 2022 Apr; 5(4):e228399. PubMed ID: 35446395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of a bilayered living cellular construct and an acellular fetal bovine collagen dressing in the treatment of venous leg ulcers.
    Sabolinski ML; Gibbons G
    J Comp Eff Res; 2018 Aug; 7(8):797-805. PubMed ID: 29809059
    [No Abstract]   [Full Text] [Related]  

  • 17. Geographic variation in Medicare spending and mortality for diabetic patients with foot ulcers and amputations.
    Sargen MR; Hoffstad O; Margolis DJ
    J Diabetes Complications; 2013; 27(2):128-33. PubMed ID: 23062327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective comparison of diabetic foot ulcer and venous stasis ulcer healing outcome between a dermal repair scaffold (PriMatrix) and a bilayered living cell therapy (Apligraf).
    Karr JC
    Adv Skin Wound Care; 2011 Mar; 24(3):119-25. PubMed ID: 21326023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bioengineered living cell construct activates metallothionein/zinc/MMP8 and inhibits TGFβ to stimulate remodeling of fibrotic venous leg ulcers.
    Stone RC; Stojadinovic O; Sawaya AP; Glinos GD; Lindley LE; Pastar I; Badiavas E; Tomic-Canic M
    Wound Repair Regen; 2020 Mar; 28(2):164-176. PubMed ID: 31674093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of three adjunct cellular/tissue-derived products used in the management of chronic venous leg ulcers.
    Carter MJ; Waycaster C; Schaum K; Gilligan AM
    Value Health; 2014 Dec; 17(8):801-13. PubMed ID: 25498775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.